TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection
Approval issued by Portuguese Medicine Regulatory Authority only 14 months after submission, versus the average 21 months
PR Newswire
BOSTON, June 1, 2020